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Few medical areas have changed as much through the
last decades as the treatment of breast cancer (BC).
From Halsted's theory of the progression of an initially
local disease, with a first loco‐regional and then metas‐
tatic extension, to the most recent studies in molecular
biology that identify the gene personality of each tumor,
there have been many advances. Old TNM classification
originally designed for solid tumors have been abando‐
ned and all areas related to hormonal dependence and
gene expression of each tumor have grown in impor‐
tance. All this is aimed at better facing a global therapeu‐
tic approach.
Almost 20 years ago, an impor‐
tant biological research laboratory
provided us with a detailed study of
the basal estradiol levels of the pa‐
tients in the placebo group of the
MORE study1. An increased risk of
breast cancer associated with raised
serum estradiol levels was demons‐
trated, confirming the previous re‐
sults on the hormonal dependence of
this neoplasm. With the introduction
of chemotherapy (QMT) in the final
decade of the last century, the gene‐
ral mortality of women from breast
cancer was reduced in all western
countries. At the time, and just a few
years later, the implementation of
massive early detection programs at
the population level facilitated an in‐
crease in the diagnosis of tumors in
early stages.
Currently, women survive BC for
many years more than just twenty
years ago, increasing the risk of va‐
rious chronic diseases, to which little
or no attention was previously given
by oncology teams. To this we must
add that treatments that seek to eli‐
minate hormonal influence such as
surgical oophorectomy, GnRH ago‐
nists, and QMT with consecutive in‐
duction of iatrogenic early ovarian
failure, may increase the risk of loss
of bone mass and the appearance of osteoporosis (OP)
in surviving women.
Breast cancer per se does not influence the increased
risk of OP. In fact, the prevalence of fractures among
patients diagnosed with untreated breast cancer and
who do not have bone metastases the frequency is si‐
milar to that of the general population2. In these
women, the bone mineral density (BMD) in the lumbar
spine, hip and radius is similar to that of healthy
women. These results are observed in both premeno‐
pausal and postmenopausal women3. Significant chan‐
ges in the biochemical markers of bone remodeling
(BMBR) have not been reported in
women with BC, at least before star‐
ting anti‐tumor treatment4. So it does
not appear that the prevalence of OP
in women with BC is increased at the
disease onset. At the same time, once
again using the placebo groups of the
trials as biological laboratories, it has
been described that the proportion of
patients with at least one event rela‐
ted to the skeleton is significantly
higher in the group with BC than in the
cancer patients generally related to
bone damage, such as multiple mye‐
loma or even prostate cancer5.
Thus, anti‐neoplastic therapy makes
the difference in surviving patients
with BC, regarding their bone risk.
Premenopausal women with BC
who receive ovarian irradiation also
have accelerated bone loss as a re‐
sult of cessation of ovarian activity.
Regarding systemic treatment, both
cytotoxic drugs and anti‐hormonal
therapies can facilitate the develop‐
ment of osteoporosis. The former,
cytotoxic agents, in addition to acting
on neoplastic cells, can alter osteo‐
blastic and gonadal activity. The main
cause of this disorder is cyclophos‐
phamide, which, along with other
drugs (methotrexate, doxorubicin,
and fluoracil), is included in classic
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The constant reduction in
mortality from breast cancer,
the diagnosis earlier and the
increasingly selective but
high intensity aggressiveness
in the therapeutic approach,
put on the table of the clini-
cians involved a new cha-
llenge: to avoid damage in
these patients bone as a tri-
bute that too many times, too
many women pay to achieve
a survival that, let us not for-
get, we are in a position to
improve with an adequate
quality of life.
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therapeutic regimens, all of which are capable of dama‐
ging the cells of the granular layer of the ovary. Gonadal
dysfunction, which is present in most women at the end
of treatment with this drug, can persist indefinitely de‐
pending on the age of the patient and the dose and du‐
ration of treatment6. Furthermore, regardless of the
duration or dose of therapy, when ovarian failure occurs,
patients develop a state of estrogenic deficiency and a
subsequent increase in bone resorption6. This increase
in resorption causes a decrease in BMD in the first years
after the cessation of menstruation, decreasing verte‐
bral bone density by 21% compared to eumenorrheic
women of the same age. QMT effects on gonadal function
seem to be responsible for the loss of bone mass that is
observed in premenopausal women with BC who undergo
QMT and that can exceed 5% per year.
By verifying the influence of QMT on fracture risk, it
has been found that it is four times higher for vertebral
fracture7. The data provided by one of the branches of
the WHI (Women's Health Initiative) showed that the
risk of presenting a vertebral or wrist clinical fracture is
increased by 30% in postmenopausal women who have
survived BC, while it does not appear that the incidence
of hip fracture increases significantly8. Other authors
also found inconclusive results for hip fracture9.
The true workhorse in the past two decades has been
the use of universal anti‐hormonal therapies in patients
with positive hormone receptor (HR) BC. The aromatase
enzyme is known to be responsible for the peripheral
conversion of androstendione and testosterone to oes‐
trone and estradiol. It is present in the breast, fat, muscle
and brain tumor tissue. The biological action of aroma‐
tase inhibitors (AI) is to block aromatase, inhibiting the
cytochrome P450 isoenzyme, responsible for the peri‐
pheral conversion of androgens to estrogens. Estrogens
maintain bone mass, and AI treatment involves rapid
bone loss due to estrogen deficiency. Given that the main
source of estrogens in postmenopause is extraovarian,
the suppression of circulating estrogens is profound in
these patients, approximately 95‐98%. Thus, their indi‐
cation is limited to postmenopausal patients. Third ge‐
neration aromatase inhibitors are divided into two
groups: steroidal or type I inactivators and non‐steroidal
or type II inhibitors. Exemestane, a steroid inhibitor and
an andrendrendione analog, irreversibly binds the aro‐
matase enzyme, while letrozole and anastrozole, type II
inhibitors, reversibly bind the enzyme. Various in vivo
animal studies suggest that exemestane (steroid) may
be less detrimental to bone health than non‐steroidal
inhibitors, perhaps because it is structurally related to
androstendione and has an affinity for the androgenic
receptor. Its main metabolite in humans and rats, 17‐
hydroxyexamestane, is also androgenic and strongly
binds to the receptor. By contrast, non‐steroids have no
proven androgenic effects10.
All clinical trials have shown that its use always im‐
proves the disease‐free survival period, and at the same
time reduces the risk of contralateral BC (the existence
of a BC being the main risk factor for the development
of a second BC in the same woman).
However, AIs are able to significantly reduce the BMD
of treated patients. In a sub‐study of the five‐year Arimi‐
dex trial, tamoxifen (TAM), alone or in combination
(ATAC), postmenopausal women with MC and anastro‐
zole therapy were found to have increased bone loss in
the lumbar spine (LS) and total hip (TH), 6 and 7.2%, res‐
pectively, compared to those assigned to TAM (increase
of 2.8 and 0.74%, respectively)11. In a substudy (206 pa‐
tients) of the Intergroup Exemestane Study (IES), in
which postmenopausal women who had taken TAM for
two or three years were randomly assigned to switch to
exemestane or to continue TAM, it was found that those
who switched to exemestane experienced a greater de‐
crease in BMD in LS (2.7%) and hip (1.4%) after six
months, compared to those who remained with TAM (wi‐
thout changes in any of the places)12. Bone loss slowed
in the remaining 18 months of the study, decreasing an
additional 1 and 0.8% in LS and TH, respectively, in sub‐
jects assigned to exemestane.
In premenopausal women, in whom the main source
of estrogen is the ovaries, AIs alone are not effective. Ho‐
wever, in combination with gonadotropin‐releasing hor‐
mone (GnRH) agonists, goserelin, AIs cause more bone
loss than TAM. In the Austrian trial of the Austrian Bre‐
ast and Colorectal Cancer Study Group (ABCSG)13, pre‐
menopausal women were randomly assigned to TAM
plus goserelin versus anastrozole plus goserelin. Half of
each group received zoledronic acid (ZOL). Significant
bone loss occurred in the subset of patients who did not
receive ZOL (reductions of 17.3 and 11.6% in patients
who received anastrozole‐goserelin and TAM‐goserelin,
respectively).
Regarding BMBRs, in several of the previously descri‐
bed assays, both bone resorption (urinary n‐telopeptide
and serum C‐telopeptide [CTX]) and training (serum
bone‐specific alkaline phosphatase [BALP], N‐terminal
propeptide 1 procollagen [P1NP]) increased signifi‐
cantly with AI treatment11‐13.
Whatever the case, the most important bone damage
in BC patients on AI treatment is the increased relative
risk (RR) of fractures. These reportedly appear in pa‐
tients of age ranges much earlier than that observed in
the general population, as early as age 50, involving
even hip fractures14. Compared to TAM, all AIs signifi‐
cantly increased the RR of fractures: anastrazole 43%
higher than TAM in one study15 and 100% in another16;
letrozole 48% in one study17, 15% in another18; exemes‐
tane 45%19.
In this issue, the first results of a large cohort in our
country of patients with BC treated with AI are published,
and these extremes of bone risk are verified20. In this
cohort of almost 1,000 patients followed consecutively
for up to five years and one after the end of their the‐
rapy, the authors observed that the main risk factor de‐
tected for incident fracture in patients treated with AI
is the diagnosis of osteopenia or osteoporosis. In their
hands, the FRAX® calculation and the determination of
β‐CTX levels were useful in identifying high‐risk pa‐
tients.
Indeed, a complete evaluation of mineral metabolism
(with measurement of BMD, RX of CL and of the thora‐
cic spine, as well as MBRO and quantification of 25 OH
vitamin D, at least) must be unequivocally part of the
diagnostic study of any BC in a pre‐patient or postme‐
nopausal. The bone risk inherent in anti‐neoplastic the‐
rapies used as part of health care after initial surgery,
either QMT or with various anti‐hormonal therapies,
particularly with AI, is frequently updated in very nota‐
ble loss of BMD in all locations with increased RR of
fractures at ages sometimes up to ten to twenty years
earlier than would be expected from the usual develop‐
ment of osteoporosis.
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The constant reduction in mortality from BC, the
diagnosis earlier and the increasingly selective but high
intensity aggressiveness in the therapeutic approach,
put on the table of the clinicians involved a new cha‐
llenge: to avoid damage in these patients bone as a tri‐
bute that too many times, too many women pay to
achieve a survival that, let us not forget, we are in a po‐
sition to improve with an adequate quality of life. In this
endeavor, the multidisciplinary care that includes the
gynecologist with the oncologist and bone metabolism
specialists (endocrinologists, rheumatologists and inter‐
nists) depending on the place, is an objective that all cen‐
ters that care for people with BC should consider more
sooner than later. It is a challenge that we all must face.
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